Bull Sessions (5/23/2023)

Prepping for the May 2023 Investing Round Table ... the floor is open. Do you have a favorite stock that is worthy of consideration at this time? Let us know. A quick look at the update logistics at Manifest Investing and some screening for Round Table. We take it seriously. The rate of return on the Round Table tracking portfolio is 15-16% since inception in 2010.

In this May 23, 2023 Bull Sessions episode, Mark Robertson and Ken Kavula provide educational commentary on market conditions and investment opportunities, with guest Kevin joining the discussion. The hosts highlight that the market appears modestly undervalued based on their technical indicators, with an improving trend in new highs versus new lows—a positive signal despite recent market volatility. They emphasize the importance of maintaining a long-term perspective when analyzing stocks, noting that analysts are often driven by momentum into excessive pessimism and optimism, creating opportunities for disciplined investors.

A significant portion of the discussion focuses on pharmaceutical companies developing Type 2 diabetes and weight-loss medications. Ken Kavula explains that Novo Nordisk and Lilly are leading efforts in this space, with Novo Nordisk's drug showing 15-17% body weight loss and Lilly's Mounjaro demonstrating 20-22% weight loss in clinical trials. Both Robertson and Kavula own stock in Novo and Lilly, and they discuss the potential $150 billion market opportunity, while cautioning investors about insurance reimbursement challenges and the need for ongoing dosage to maintain results.

The hosts also celebrate the expansion of the Manifest Investing Millionaires Club portfolio contest, which now has 28-29 entries exceeding $1 million in value, and provide clarifications on how company reports are updated—noting that fundamental data is now updated continuously through YCharts and other online sources rather than relying solely on the historical Value Line update cycle.